Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis | 19 | 2024 | 90 | 6.370 |
Why?
|
| Osteoarthritis, Knee | 7 | 2019 | 51 | 3.000 |
Why?
|
| Pain | 10 | 2024 | 47 | 2.660 |
Why?
|
| Hyperalgesia | 6 | 2024 | 25 | 2.110 |
Why?
|
| Animals | 28 | 2024 | 1050 | 2.010 |
Why?
|
| Arthritis, Experimental | 5 | 2018 | 25 | 1.870 |
Why?
|
| Nociceptors | 5 | 2019 | 15 | 1.790 |
Why?
|
| Arthralgia | 4 | 2019 | 25 | 1.710 |
Why?
|
| Mice | 22 | 2024 | 343 | 1.640 |
Why?
|
| Disease Models, Animal | 17 | 2024 | 174 | 1.560 |
Why?
|
| Neurons | 3 | 2017 | 55 | 1.460 |
Why?
|
| Knee Joint | 4 | 2024 | 43 | 1.430 |
Why?
|
| Chronic Pain | 4 | 2020 | 20 | 1.300 |
Why?
|
| Nociception | 4 | 2019 | 9 | 1.300 |
Why?
|
| Ganglia, Spinal | 7 | 2024 | 25 | 1.010 |
Why?
|
| Male | 18 | 2024 | 1860 | 0.980 |
Why?
|
| Humans | 24 | 2020 | 2957 | 0.960 |
Why?
|
| Chemokine CCL2 | 5 | 2018 | 17 | 0.930 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 88 | 0.760 |
Why?
|
| Analgesics | 2 | 2020 | 20 | 0.750 |
Why?
|
| Cytokines | 6 | 2019 | 33 | 0.740 |
Why?
|
| Nerve Growth Factor | 3 | 2024 | 11 | 0.680 |
Why?
|
| Calcium | 3 | 2018 | 231 | 0.670 |
Why?
|
| Pain Management | 2 | 2018 | 27 | 0.660 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2020 | 3 | 0.650 |
Why?
|
| Neuroimmunomodulation | 2 | 2019 | 4 | 0.650 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2018 | 7 | 0.640 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 3 | 0.630 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 3 | 0.630 |
Why?
|
| Receptors, CCR2 | 3 | 2017 | 7 | 0.630 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 3 | 0.610 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 14 | 0.600 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 32 | 0.600 |
Why?
|
| Aggrecans | 2 | 2018 | 10 | 0.570 |
Why?
|
| ADAM Proteins | 2 | 2015 | 4 | 0.570 |
Why?
|
| Behavior, Animal | 2 | 2024 | 20 | 0.570 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2015 | 7 | 0.560 |
Why?
|
| Clozapine | 1 | 2017 | 2 | 0.520 |
Why?
|
| Neural Inhibition | 1 | 2017 | 4 | 0.520 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 8 | 0.500 |
Why?
|
| Mice, Knockout | 5 | 2018 | 67 | 0.490 |
Why?
|
| Chemokine CX3CL1 | 1 | 2016 | 2 | 0.490 |
Why?
|
| Microglia | 1 | 2016 | 12 | 0.490 |
Why?
|
| Stifle | 1 | 2015 | 3 | 0.460 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 7 | 0.460 |
Why?
|
| Joints | 2 | 2014 | 15 | 0.430 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 2 | 0.400 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 2 | 0.400 |
Why?
|
| Cartilage, Articular | 5 | 2018 | 70 | 0.380 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 40 | 0.380 |
Why?
|
| Female | 6 | 2024 | 1724 | 0.360 |
Why?
|
| Macrophages | 2 | 2024 | 13 | 0.310 |
Why?
|
| Menisci, Tibial | 3 | 2017 | 7 | 0.300 |
Why?
|
| Immunity, Innate | 2 | 2019 | 7 | 0.290 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 10 | 0.260 |
Why?
|
| Biomarkers | 2 | 2019 | 101 | 0.260 |
Why?
|
| ADAMTS5 Protein | 2 | 2018 | 5 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 11 | 0.250 |
Why?
|
| Signal Transduction | 2 | 2019 | 97 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 27 | 0.230 |
Why?
|
| Synovial Membrane | 2 | 2017 | 10 | 0.220 |
Why?
|
| Microscopy | 1 | 2024 | 6 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 33 | 0.210 |
Why?
|
| Mutation | 2 | 2020 | 77 | 0.190 |
Why?
|
| Collagen Type V | 1 | 2020 | 3 | 0.160 |
Why?
|
| Skin | 1 | 2020 | 22 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2020 | 17 | 0.150 |
Why?
|
| Synovitis | 1 | 2019 | 8 | 0.150 |
Why?
|
| Alarmins | 1 | 2019 | 2 | 0.150 |
Why?
|
| Disease Progression | 1 | 2019 | 99 | 0.150 |
Why?
|
| Cells, Cultured | 2 | 2015 | 119 | 0.140 |
Why?
|
| ADAMTS4 Protein | 1 | 2018 | 3 | 0.140 |
Why?
|
| Ganglion Cysts | 1 | 2018 | 3 | 0.140 |
Why?
|
| Matrix Metalloproteinases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Neurons, Afferent | 1 | 2018 | 3 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2018 | 54 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 32 | 0.140 |
Why?
|
| Central Nervous System Sensitization | 1 | 2017 | 3 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 161 | 0.130 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 4 | 0.130 |
Why?
|
| Rats | 1 | 2018 | 234 | 0.130 |
Why?
|
| Arthritis | 4 | 1999 | 4 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 3 | 0.130 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 5 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 9 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 1999 | 30 | 0.130 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 49 | 0.130 |
Why?
|
| Chemokines, CC | 1 | 2017 | 2 | 0.130 |
Why?
|
| Osteonecrosis | 1 | 2017 | 4 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 4 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 10 | 0.130 |
Why?
|
| Reference Values | 1 | 2016 | 28 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2016 | 13 | 0.120 |
Why?
|
| Random Allocation | 1 | 2016 | 23 | 0.120 |
Why?
|
| Proteoglycans | 2 | 1994 | 23 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 74 | 0.120 |
Why?
|
| Calgranulin A | 1 | 2015 | 3 | 0.120 |
Why?
|
| alpha-Macroglobulins | 1 | 2015 | 11 | 0.120 |
Why?
|
| Tibial Meniscus Injuries | 1 | 2015 | 2 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 2 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 4 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2015 | 24 | 0.110 |
Why?
|
| Spinal Diseases | 1 | 1994 | 2 | 0.100 |
Why?
|
| Intestines | 1 | 1994 | 3 | 0.100 |
Why?
|
| Joint Diseases | 1 | 1994 | 5 | 0.100 |
Why?
|
| Catalysis | 1 | 2013 | 7 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 4 | 0.100 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 6 | 0.100 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 12 | 0.100 |
Why?
|
| Synovial Fluid | 2 | 2012 | 23 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2012 | 59 | 0.090 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 4 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2012 | 26 | 0.080 |
Why?
|
| Collagen | 3 | 1999 | 24 | 0.080 |
Why?
|
| Aged | 4 | 2017 | 956 | 0.060 |
Why?
|
| Middle Aged | 3 | 2017 | 792 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2012 | 15 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 2 | 1994 | 2 | 0.050 |
Why?
|
| Interleukin-12 | 2 | 1999 | 4 | 0.050 |
Why?
|
| Gene Expression | 3 | 2016 | 45 | 0.040 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 2 | 0.040 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2019 | 4 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 1999 | 8 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 1997 | 1 | 0.030 |
Why?
|
| Th1 Cells | 1 | 1997 | 1 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1997 | 4 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 18 | 0.030 |
Why?
|
| Sepharose | 2 | 1994 | 2 | 0.030 |
Why?
|
| Rheumatoid Nodule | 2 | 1993 | 2 | 0.030 |
Why?
|
| Cricetinae | 1 | 2015 | 16 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 13 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1995 | 1 | 0.030 |
Why?
|
| Thoracic Diseases | 1 | 1995 | 1 | 0.030 |
Why?
|
| Epitopes | 1 | 2015 | 6 | 0.030 |
Why?
|
| Adult | 1 | 2017 | 794 | 0.030 |
Why?
|
| Mice, Inbred DBA | 3 | 1999 | 3 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1994 | 9 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1994 | 13 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1994 | 1 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1994 | 57 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1994 | 21 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1993 | 1 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 1 | 0.020 |
Why?
|
| HIV Infections | 1 | 1994 | 103 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2012 | 5 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1992 | 2 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1992 | 7 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1992 | 6 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1990 | 1 | 0.020 |
Why?
|
| Immunotherapy | 2 | 1999 | 5 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 17 | 0.020 |
Why?
|
| Down-Regulation | 2 | 1999 | 22 | 0.020 |
Why?
|
| CD4 Antigens | 2 | 1997 | 5 | 0.010 |
Why?
|
| Clone Cells | 2 | 1993 | 4 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 4 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 7 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1999 | 5 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1999 | 72 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 16 | 0.010 |
Why?
|
| Rolipram | 1 | 1997 | 1 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 17 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 8 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 11 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 1 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 8 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1995 | 69 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1993 | 3 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1993 | 3 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1993 | 6 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 11 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1993 | 23 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1992 | 3 | 0.010 |
Why?
|
| Ileum | 1 | 1992 | 5 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 16 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1990 | 1 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1990 | 1 | 0.010 |
Why?
|
| Gels | 1 | 1990 | 2 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1990 | 8 | 0.010 |
Why?
|
| Hyaluronic Acid | 1 | 1990 | 7 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1990 | 35 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1990 | 83 | 0.000 |
Why?
|